Insider Trading activities of Anthera Pharmaceuticals Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anthera Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Anthera Pharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Anthera Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is ANTH. The reporting company's CIK number is 1316175.
The total value of stock buying since 2005 is $6,011,494.
The total value of stock sales since 2005 is $24,150,557.
The total value of stock option exercises since 2005 is $492,027.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Anthera Pharmaceuticals Inc (ANTH).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-09 13,550 $17,986 0 $0 10,400 $14,892
2016-09 0 $0 0 $0 5,008 $10,416
2015-12 0 $0 0 $0 10,000 $28,900
2015-11 0 $0 17,500 $93,237 12,500 $20,125
2015-10 0 $0 1,205 $7,410 0 $0
2014-06 0 $0 0 $0 2,000 $4,160
2013-06 100,000 $53,000 0 $0 0 $0
2013-05 10,000 $5,900 0 $0 0 $0
2013-01 7,462,000 $4,903,776 0 $0 0 $0
2012-06 220,000 $165,000 1,283,300 $941,942 0 $0
2012-03 0 $0 1,550,500 $3,849,993 0 $0
2012-02 0 $0 62,000 $493,839 40,000 $10,400
2012-01 0 $0 17,000 $114,255 32,000 $55,480
2011-12 0 $0 221,200 $1,418,370 0 $0
2011-11 0 $0 172,000 $1,181,380 15,000 $3,900
2011-10 0 $0 34,617 $220,157 0 $0
2011-08 0 $0 19,600 $138,438 60,000 $26,400
2011-07 0 $0 15,000 $119,250 34,563 $49,814
2011-06 0 $0 120,099 $979,150 30,000 $19,100
2011-05 0 $0 1,929,251 $14,593,136 0 $0
2011-04 0 $0 0 $0 33,311 $12,799
2011-01 0 $0 0 $0 11,558 $16,470
2010-09 275,900 $856,292 0 $0 19,063 $10,430
2010-08 500 $2,400 0 $0 0 $0
2010-04 0 $0 0 $0 64,251 $45,669
2010-03 1,000 $7,140 0 $0 129,895 $163,072

Table 2. Detailed insider stock purchases, sales, and option exercises of Anthera Pharmaceuticals Inc insiders (ANTH)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-09-20 Thompson John Craig (President & CEO) Buy 8,550 1.32 11,286
2017-09-07 Thompson John Craig (President & CEO) Option Ex 10,400 1.43 14,892
2017-09-07 Truex Paul F Buy 5,000 1.34 6,700
2016-09-20 Truex Paul F (Chief Executive Officer) Option Ex 5,008 2.08 10,416
2015-12-23 Mueller Brian Option Ex 10,000 2.89 28,900
2015-11-13 Hislop Colin (Chief Medical Officer) Sale 12,500 5.31 66,337
2015-11-13 Hislop Colin (Chief Medical Officer) Option Ex 12,500 1.61 20,125
2015-11-11 Hislop Colin (Chief Medical Officer) Sale 5,000 5.38 26,900
2015-10-12 Odink Debra (Chief Technology Officer) Sale 1,205 6.15 7,410
2014-06-30 Truex Paul F (President and CEO) Option Ex 2,000 2.08 4,160
2013-06-24 Thompson David E. Buy 100,000 .53 53,000
2013-05-31 Dziurzynski Bogdan Buy 10,000 .59 5,900
2013-01-30 Isaly Samuel D Buy 5,700,000 .66 3,762,000
2013-01-25 Isaly Samuel D Buy 1,762,000 .65 1,141,776
2012-06-29 Henney Christopher S (Director) Buy 200,000 .75 149,800
2012-06-29 Truex Paul F (President and CEO) Buy 20,000 .76 15,200
2012-06-29 Isaly Samuel D Sale 1,283,300 .73 941,942
2012-03-22 Isaly Samuel D Sale 1,306,700 2.40 3,140,000
2012-03-21 Isaly Samuel D Sale 125,000 2.87 358,250
2012-03-20 Isaly Samuel D Sale 116,800 2.90 338,603
2012-03-01 Odink Debra (Chief Technology Officer) Sale 2,000 6.57 13,140
2012-02-23 Hislop Colin (Chief Medical Officer) Option Ex 40,000 .26 10,400
2012-02-15 Truex Paul F (President and C.E.O.) Sale 15,000 7.84 117,600
2012-02-03 Hislop Colin (Chief Medical Officer) Sale 30,000 8.20 245,999
2012-02-01 Lowe Christopher P. (C.F.O. and C.B.O.) Sale 15,000 7.66 114,900
2012-02-01 Odink Debra (Chief Technology Officer) Sale 2,000 7.67 15,340
2012-01-31 Truex Paul F (President and C.E.O.) Option Ex 20,000 .26 5,200
2012-01-28 Healy James (Director) Option Ex 12,000 4.19 50,280
2012-01-17 Truex Paul F (President and Chief Executive) Sale 15,000 6.75 101,250
2012-01-10 Odink Debra (Chief Technology Officer) Sale 800 6.51 5,205
2012-01-06 Odink Debra (Chief Technology Officer) Sale 1,200 6.50 7,800
2011-12-30 Buatois Eric (10% Owner) Sale 25,000 6.22 155,625
2011-12-30 Healy James (Director) Sale 25,000 6.22 155,625
2011-12-22 Buatois Eric (10% Owner) Sale 25,000 6.22 155,600
2011-12-22 Healy James (Director) Sale 25,000 6.22 155,600
2011-12-21 Buatois Eric (10% Owner) Sale 25,000 6.51 162,775
2011-12-21 Healy James (Director) Sale 25,000 6.51 162,775
2011-12-15 Truex Paul F (President and CEO) Sale 15,000 6.34 95,070
2011-12-13 Isaly Samuel D Sale 16,200 6.50 105,300
2011-12-09 Isaly Samuel D Sale 40,000 6.75 270,000
2011-11-18 Isaly Samuel D Sale 3,000 6.50 19,500
2011-11-17 Isaly Samuel D Sale 24,000 6.67 160,080
2011-11-16 Isaly Samuel D Sale 25,000 6.87 171,750
2011-11-15 Truex Paul F (President and CEO) Sale 30,000 6.96 208,710
2011-11-15 Isaly Samuel D Sale 50,000 6.93 346,500
2011-11-14 Isaly Samuel D Sale 5,000 6.95 34,750
2011-11-11 Isaly Samuel D Sale 5,000 7.14 35,700
2011-11-08 Hislop Colin (Chief Medical Officer) Sale 15,000 6.74 101,160
2011-11-08 Hislop Colin (Chief Medical Officer) Option Ex 15,000 .26 3,900
2011-11-03 Lowe Christopher P. (Chief Financial Officer & CBO) Sale 15,000 6.88 103,230
2011-10-25 Lowe Christopher P. (Chief Financial Officer & CBO) Sale 4,637 7.07 32,783
2011-10-21 Truex Paul F (President and CEO) Sale 23,235 6.25 145,218
2011-10-18 Truex Paul F (President and CEO) Sale 6,745 6.25 42,156
2011-08-08 Lowe Christopher P. (Chief Financial Officer & CBO) Option Ex 10,000 1.34 13,400
2011-08-08 Truex Paul F (President and CEO) Option Ex 50,000 .26 13,000
2011-08-03 Lowe Christopher P. (Chief Financial Officer & CBO) Sale 14,600 6.88 100,433
2011-08-02 Lowe Christopher P. (Chief Financial Officer & CBO) Sale 5,000 7.60 38,005
2011-07-15 Truex Paul F (President and CEO) Sale 15,000 7.95 119,250
2011-07-12 Hislop Colin (Chief Medical Officer) Option Ex 15,000 .26 3,900
2011-07-07 Salzman Alan E Option Ex 19,563 2.35 45,914
2011-06-29 Hislop Colin (Chief Medical Officer) Option Ex 10,000 .26 2,600
2011-06-21 Lowe Christopher P. (Chief Financial Officer & CBO) Option Ex 20,000 .82 16,500
2011-06-16 Salzman Alan E Sale 3,100 8.67 26,877
2011-06-15 Truex Paul F (President and CEO) Sale 15,000 8.30 124,545
2011-06-14 Salzman Alan E Sale 699 8.81 6,158
2011-06-13 Salzman Alan E Sale 1,300 8.80 11,440
2011-06-10 Isaly Samuel D Sale 30,000 8.18 245,400
2011-06-09 Isaly Samuel D Sale 37,000 8.11 300,070
2011-06-08 Isaly Samuel D Sale 33,000 8.02 264,660
2011-05-26 Salzman Alan E Sale 4,800 8.60 41,280
2011-05-26 Isaly Samuel D Sale 34,200 8.53 291,726
2011-05-25 Salzman Alan E Sale 32,750 8.67 283,942
2011-05-25 Isaly Samuel D Sale 4,800 8.65 41,520
2011-05-24 Salzman Alan E Sale 52,196 8.42 439,490
2011-05-23 Salzman Alan E Sale 26,703 8.18 218,430
2011-05-19 Salzman Alan E Sale 125,000 8.03 1,003,749
2011-05-18 Isaly Samuel D Sale 138,668 8.03 1,113,504
2011-05-17 Salzman Alan E Sale 13,900 8.29 115,230
2011-05-17 Isaly Samuel D Sale 200,000 8.32 1,664,000
2011-05-16 Truex Paul F (President and CEO) Sale 15,000 7.16 107,340
2011-05-16 Isaly Samuel D Sale 24,000 7.20 172,800
2011-05-11 Isaly Samuel D Sale 26,000 7.22 187,720
2011-05-10 Isaly Samuel D Sale 212,800 7.23 1,538,544
2011-05-09 Isaly Samuel D Sale 20,000 7.26 145,200
2011-05-05 Salzman Alan E Sale 387,700 7.01 2,717,777
2011-05-04 Salzman Alan E Sale 200,000 7.00 1,400,000
2011-05-03 Salzman Alan E Sale 100,000 7.00 700,000
2011-04-13 Odink Debra (VP, Pharmaceutical R&D) Option Ex 3,311 1.51 4,999
2011-04-13 Truex Paul F (President and CEO) Option Ex 30,000 .26 7,800
2011-01-03 Thompson David E. (Director) Option Ex 11,558 1.43 16,470
2010-09-30 Isaly Samuel D Buy 19,900 4.08 81,192
2010-09-24 Leheny A. Rachel (Director) Buy 250,000 3.00 750,000
2010-09-24 Lowe Christopher P. (CFO & VP of Administration) Buy 5,000 4.18 20,900
2010-09-24 Odink Debra (VP, Pharmaceutical R&D) Buy 1,000 4.20 4,200
2010-09-21 Trias Joaquim (Sr. VP, Preclinical Developmen) Option Ex 4,380 1.51 6,613
2010-09-21 Hislop Colin (Sr. VP, Cardiovasc. Prod.) Option Ex 14,683 .26 3,817
2010-08-18 Hislop Colin (Sr. VP, Cardiovasc. Prod.) Buy 500 4.80 2,400
2010-04-07 Truex Paul F (President and CEO) Option Ex 23,364 .14 3,270
2010-04-01 Henney Christopher S (Director) Option Ex 40,887 1.04 42,399
2010-03-31 Lowe Christopher P. (CFO & VP of Administration) Option Ex 9,637 .20 1,927
2010-03-04 Leheny A. Rachel (Director) Option Ex 120,258 1.34 161,145
2010-03-01 Truex Paul F (President and CEO) Buy 1,000 7.14 7,140

Insider trading activities including stock purchases, stock sales, and option exercises of ANTH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Anthera Pharmaceuticals Inc (symbol ANTH, CIK number 1316175) see the Securities and Exchange Commission (SEC) website.